Dr. Allué Guardia received her Ph.D. in Environmental Microbiology and Biotechnology from the University of Barcelona in 2014. She joined Texas Biomed in 2018 after her postdoctoral appointments, where she used multi-omic approaches to study different bacterial pathogens. She currently seeks to understand how M. tuberculosis adapts to our lungs during the first stages of infection, and how early events are critical drivers of infection outcomes. Specifically, she studies how the alveolar lining fluid (ALF) modifies the cell envelope and metabolism of M.tb. Her ultimate goal is to identify early host and pathogen factors that could serve as novel targets for tuberculosis treatment and diagnostics. She is also engaged in COVID-19 research, including the validation of small animal models and in vitro 3D systems for studying SARS-CoV-2 infection. Using Next Generation Sequencing technologies, she seeks to create novel strategies to combat infectious diseases.